Table 2. Patient characteristics—we report a case series of 11 consecutive patients with fluoropyrimidine-induced chest pain who have been rechallenged with the culprit drug.
| Patient # | Malignancy diagnosis | Age/sex | First treatment | Cardiac risk factors | Imaging or diagnostic modality |
|---|---|---|---|---|---|
| 1 | Colorectal carcinoma | 48/male | Capecitabine | Nuclear stress | |
| 2 | Peritoneal carcinoma | 66/male | FOLFOX | Hypertension; hyperlipidemia | CTA |
| 3 | Colorectal carcinoma | 68/female | FOLFOX | COR | |
| 4 | Esophageal carcinoma | 51/male | FOLFOX | COR | |
| 5 | Colorectal carcinoma | 74/male | FOLFOX | COR | |
| 6 | Metastatic breast carcinoma | 66/female | Capecitabine | CTA | |
| 7 | Colorectal carcinoma | 49/female | FOLFOX | Exercise echo | |
| 8 | Colorectal carcinoma | 64/male | FOLFOX | Hypertension; hyperlipidemia | CTA |
| 9 | Colorectal carcinoma | 56/female | FOLFOX | Nuclear stress | |
| 10 | Colorectal carcinoma | 60/female | FOLFOX | CTA | |
| 11 | Breast carcinoma | 70/female | Capecitabine | Diabetes; hypertension | COR |
Nuclear stress, nuclear stress test; FOLFOX, folinic acid, fluorouracil and oxaliplatin; CTA, computed tomography angiography; COR, coronary angiography; Exercise Echo, exercise echocardiographgy.